ACADIA Pharmaceuticals Azioni (NASDAQ: ACAD)

Ultime notizie per ACADIA Pharmaceuticals (NASDAQ:ACAD) Azioni

ACADIA PHARMACEUTICALS INC

ACADIA Pharmaceuticals

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.

ACADIA Pharmaceuticals Inc. - Common Stock

ACADIA Pharmaceuticals Inc

Academy Sports and Outdoors, Inc. - Common Stock

Academy Sports and Outdoors Inc

ACADIA ENERGY CORP by Acadia Energy Corporation

Acadia Energy Corp

Acadia Healthcare Company, Inc. - Common Stock

Acadia Healthcare Co Inc

Acadia Realty Trust

Acadian Asset Management Inc. Common Stock

Acadian Asset Management Inc

ACADIAN TIMBER CORP ORD by Acadian Timber Corp

Acadian Timber Corp

Deutsche Bank analyst David Hoang upgrades ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) from Hold to Buy and raises the price target from $20 to $35.

News

Upgrades

Price Target

Analyst Ratings

ACAD

Deutsche Bank Upgrades ACADIA Pharmaceuticals to Buy, Raises Price Target to $35

Morgan Stanley analyst Jeffrey Hung maintains ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) with a Equal-Weight and raises the price target from $20 to $24.

Morgan Stanley Maintains Equal-Weight on ACADIA Pharmaceuticals, Raises Price Target to $24

Mizuho analyst Uy Ear maintains ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) with a Neutral and raises the price target from $20 to $23.

Mizuho Maintains Neutral on ACADIA Pharmaceuticals, Raises Price Target to $23

Baird analyst Joel Beatty maintains ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) with a Outperform and raises the price target from $28 to $31.

Baird Maintains Outperform on ACADIA Pharmaceuticals, Raises Price Target to $31

RBC Capital analyst Gregory Renza reiterates ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) with a Outperform and maintains $26 price target.

Reiteration

RBC Capital Reiterates Outperform on ACADIA Pharmaceuticals, Maintains $26 Price Target

BMO Capital analyst Evan David Seigerman maintains ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) with a Outperform and raises the price target from $24 to $28.

BMO Capital Maintains Outperform on ACADIA Pharmaceuticals, Raises Price Target to $28

ACADIA Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) announced a favorable <a href="https://www.benzinga.com/quote/ACAD">court ruling on Friday</a>.
The U.S. District Court for the District of Delaware upheld the validity and found infringement of Acadia&#8217;s ‘721 formulation patent for NUPLAZID (pimavanserin), a treatment for Parkinson's Disease Psychosis.
The decision protects the 34 mg capsule formulation from generic competition until 2038, blocking challenges from Aurobindo Pharma and other generic drugmakers.
&#8220;We are very pleased with today&#8217;s decisive ruling in our favor, which provides patent protection for NUPLAZID 34 mg capsule formulation into 2038,&#8221; said Catherine Owen Adams, Chief Executive Officer. &#8220;This result highlights Acadia&#8217;s dedication to safeguarding our advancements in therapies for conditions with significant unmet medical needs.&#8221;
ACADIA Pharmaceuticals shares gained 26.5% to close at $22.26 on Friday.
These analysts made changes to their price targets on ACADIA Pharmaceuticals following the announcement.
<ul class="wp-block-list">
<li>Needham analyst Ami Fadia maintained ACADIA Pharmaceuticals with a Buy and raised the price target from $27 to $30.</li>
<li>HC Wainwright &amp; Co. analyst Andrew Fein maintained the stock with a Buy and boosted the price target from $27 to $32.</li>
</ul>
Considering buying ACAD stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="638" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19082408/image-230-1024x638.png" alt="" class="wp-image-919746" style="width:687px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19082408/image-230-1024x638.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19082408/image-230-300x187.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19082408/image-230-768x479.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19082408/image-230.png 1075w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45490061/5-stock-picks-last-week-from-wall-streets-most-accurate-analysts-6">5 Stock Picks Last Week From Wall Street&#8217;s Most Accurate Analysts</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Markets

Trading Ideas

These Analysts Boost Their Forecasts On Acadia Pharmaceuticals

In the preceding three months, 8 analysts have released ratings for ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>), presenting a wide array of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $26.88, a high estimate of $32.00, and a low estimate of $20.00. Witnessing a positive shift, the current average has risen by 2.4% from the previous average price target of $26.25.
<img src="https://www.benzinga.com/files/images/story/2025/1747656047_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The analysis of recent analyst actions sheds light on the perception of ACADIA Pharmaceuticals by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$32.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$30.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$22.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$28.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Jeffrey Hung</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$28.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$27.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$28.00</td>
<td>$28.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to ACADIA Pharmaceuticals. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of ACADIA Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for ACADIA Pharmaceuticals's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of ACADIA Pharmaceuticals's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ACAD/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on ACADIA Pharmaceuticals analyst ratings.</a>
<h2>About ACADIA Pharmaceuticals</h2>
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
<h3>A Deep Dive into ACADIA Pharmaceuticals's Financials</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: ACADIA Pharmaceuticals's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 18.7%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: ACADIA Pharmaceuticals's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 7.77%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): ACADIA Pharmaceuticals's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 2.53%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.64%, the company showcases effective utilization of assets.
Debt Management: ACADIA Pharmaceuticals's debt-to-equity ratio is below the industry average. With a ratio of 0.07, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 8 Analyst Projections For ACADIA Pharmaceuticals

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Needham raised ACADIA Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) price target from $27 to $30. Needham analyst Ami Fadia maintained a Buy rating. ACADIA Pharmaceuticals shares closed at $22.26 on Friday. <a href="https://www.benzinga.com/quote/ACAD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies cut the price target for BP p.l.c. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BP#NYSE">BP</a>) from $40.8 to $29. Jefferies analyst Giacomo Romeo downgraded the stock from Buy to Hold. BP shares closed at $29.76 on Friday. <a href="https://www.benzinga.com/quote/BP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan boosted Marqeta, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MQ#NASDAQ">MQ</a>) price target from $5 to $6. JP Morgan analyst Tien-Tsin Huang upgraded the stock from Neutral to Overweight. Marqeta shares closed at $5.04 on Friday. <a href="https://www.benzinga.com/quote/MQ/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan raised the price target for Netflix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) from $1,150 to $1,220. JP Morgan analyst Doug Anmuth downgraded the stock from Overweight to Neutral. Netflix shares closed at $1,191.53 on Friday. <a href="https://www.benzinga.com/quote/NFLX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Barclays raised the price target for Williams-Sonoma, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) from $131 to $166. Barclays analyst Seth Sigman upgraded the stock from Underweight to Equal-Weight. Williams-Sonoma shares closed at $173.84 on Friday. <a href="https://www.benzinga.com/quote/WSM/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. raised ACADIA Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) price target from $27 to $32. HC Wainwright &amp; Co. analyst Andrew Fein maintained a Buy rating. ACADIA Pharmaceuticals shares settled at $22.26 on Friday. <a href="https://www.benzinga.com/quote/ACAD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Loop Capital raised Charter Communications, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) price target from $430 to $510. Loop Capital analyst Alan Gould upgraded the stock from Hold to Buy. Charter Communications shares closed at $427.25 on Friday. <a href="https://www.benzinga.com/quote/CHTR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Citigroup cut Helmerich &amp; Payne, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HP#NYSE">HP</a>) price target from $25 to $19. Citigroup analyst Scott Gruber downgraded the stock from Buy to Neutral. Helmerich &amp; Payne shares closed at $17.80 on Friday.  <a href="https://www.benzinga.com/quote/HP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS increased the price target for Delta Air Lines, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>) from $46 to $66. UBS analyst Thomas Wadewitz upgraded the stock from Neutral to Buy. Delta Air Lines shares settled at $50.92 on Friday. <a href="https://www.benzinga.com/quote/DAL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS raised Archer-Daniels-Midland Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADM#NYSE">ADM</a>) price target from $55 to $60. UBS analyst Manav Gupta upgraded the stock from Neutral to Buy. Archer-Daniels-Midland shares closed at $50.13 on Friday. <a href="https://www.benzinga.com/quote/adm/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying NFLX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="598" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19075050/image-226-1024x598.png" alt="" class="wp-image-919670" style="width:637px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19075050/image-226-1024x598.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19075050/image-226-300x175.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19075050/image-226-768x449.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19075050/image-226.png 1121w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45490061/5-stock-picks-last-week-from-wall-streets-most-accurate-analysts-6">5 Stock Picks Last Week From Wall Street&#8217;s Most Accurate Analysts</a> </li>
</ul>
Photo via Shutterstock

CHTR

NFLX

Netflix To $1,220? Here Are 10 Top Analyst Forecasts For Monday

HC Wainwright &amp; Co. analyst Andrew Fein maintains ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) with a Buy and raises the price target from $27 to $32.

HC Wainwright & Co. Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $32

Needham analyst Ami Fadia maintains ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) with a Buy and raises the price target from $27 to $30.

Needham Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $30

ACADIA Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) stock jumped 26.6% to $22.29 on Friday afternoon following a <a href="https://www.benzinga.com/pressreleases/25/05/b45474227/delaware-district-court-rules-in-favor-of-acadia-in-nuplazid-pimavanserin-formulation-patent-litig">favorable court ruling</a>.
What To Know: The U.S. District Court for the District of Delaware upheld the validity and found infringement of Acadia's ‘721 formulation patent for NUPLAZID (pimavanserin), a treatment for Parkinson&#8217;s Disease Psychosis. 
The decision protects the 34 mg capsule formulation from generic competition until 2038, blocking challenges from Aurobindo Pharma and other generic drugmakers. 
Acadia CEO Catherine Owen Adams praised the ruling as a major win, emphasizing the company's commitment to protecting innovations that address serious unmet medical needs.
Read Also: <a href="https://www.benzinga.com/trading-ideas/movers/25/05/45474770/adobe-shares-climb-as-short-interest-drops-and-technicals-improve-whats-going-on">Adobe Shares Climb As Short Interest Drops And Technicals Improve: What&#8217;s Going On?</a>
<h2 class="wp-block-heading">How To Buy ACAD Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in ACADIA Pharmaceuticals&#8217; case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, ACAD has a 52-week high of $25.23 and a 52-week low of $13.40.

Acadia Pharmaceuticals (ACAD) Stock Explodes 26% After Patent Court Victory

<h3>Gainers</h3>
<ul>
<li>Inozyme Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INZY#NASDAQ">INZY</a>) stock moved upwards by 178.2% to $3.95 during Friday's regular session. The company's market cap stands at $253.7 million. As per the press release, Q1 earnings came out 2 days ago. </li>
<li>Rani Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RANI#NASDAQ">RANI</a>) stock increased by 26.52% to $0.72. The company's market cap stands at $24.2 million. As per the press release, Q1 earnings came out 3 days ago. </li>
<li>ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) shares increased by 25.62% to $22.11. The market value of their outstanding shares is at $3.7 billion. </li>
<li>Biodesix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDSX#NASDAQ">BDSX</a>) stock moved upwards by 25.47% to $0.28. The company's market cap stands at $40.0 million. As per the press release, Q1 earnings came out 3 days ago. </li>
<li>Agape ATP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) stock moved upwards by 25.33% to $1.88. The company's market cap stands at $94.0 million. The company's, Q1 earnings came out yesterday. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) shares increased by 22.8% to $5.43. The market value of their outstanding shares is at $3.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares declined by 67.3% to $0.01 during Friday's regular session. </li>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) shares fell 22.48% to $0.01. </li>
<li>Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) shares decreased by 19.63% to $0.65. The company's, Q2 earnings came out yesterday. </li>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) shares fell 18.92% to $0.04. </li>
<li>Lantern Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>) stock declined by 18.44% to $3.15. The company's market cap stands at $33.9 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Aytu BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AYTU#NASDAQ">AYTU</a>) stock declined by 18.15% to $2.12. The company's market cap stands at $13.0 million. As per the press release, Q3 earnings came out 2 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

APDN

ATPC

AYTU

BDSX

HCTI

INZY

LTRN

NCNA

PLRZ

RANI

12 Health Care Stocks Moving In Friday's Intraday Session

U.S. stocks were mixed, with the Dow Jones index gaining around 0.1% on Friday.
Shares of Evolv Technologies Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVLV#NASDAQ">EVLV</a>) rose sharply during Friday's session after the <a href="https://www.benzinga.com/quote/EVLV">company announced preliminary first-quarter financial results.</a>
The company said it expects revenue growth of 40%+ in the first quarter.
Evolv Technologies shares jumped 21% to $5.08 on Friday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul class="wp-block-list">
<li>Quantum Computing Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) jumped 33.7% to $12.34 after the company reported better-than-expected quarterly EPS results.</li>
<li>NWTN Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWTN#NASDAQ">NWTN</a>) gained 30.2% to $1.64. NWTN announced the appointment of Mr. Benjamin Zhai as Executive Director of the Board and Global Chief Executive Officer.</li>
<li>ACADIA Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) rose 29% to $22.70 after a court decision ruled in favor of the company regarding patent infringement claims over Nuplazid.</li>
<li>Advantage Solutions Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADV#NASDAQ">ADV</a>) gained 24.7% to $1.3596.</li>
<li>CoreWeave, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>) gained 18.5% to $77.95 after Nvidia disclosed it added a stake in the company via a 13F filing equating to approximately 24.18 million shares. Additionally, JP Morgan and Needham raised their respective price targets on the stock.</li>
<li>Applied Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) gained 18.5% to $6.64.</li>
<li>Semler Scientific, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) rose 14.4% to $36.36.</li>
<li>Archer Aviation Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NASDAQ">ACHR</a>) surged 10.3% to $13.45.</li>
<li>Vipshop Holdings Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VIPS#NYSE">VIPS</a>) rose 7.5% to $15.59. Vipshop will announce first quarter 2025 financial results on May 20.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) gained 7% to $430.00.</li>
<li>Coinbase Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) rose 6.8% to $261.17 after the company announced a partnership with Webull Pay to power crypto experiences. Additionally, Benchmark raised its price target on the stock from $252 to $301.</li>
<li>Halozyme Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) gained 5% to $51.35.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45462276/applied-materials-flowers-foods-and-3-stocks-to-watch-heading-into-friday">Applied Materials, Flowers Foods And 3 Stocks To Watch Heading Into Friday</a></li>
</ul>
Photo via Shutterstock

Intraday Update

ACHR

APLD

COIN

CRWV

EVLV

HALO

NWTN

QUBT

SMLR

VIPS

Evolv Technologies, Quantum Computing, ACADIA Pharmaceuticals And Other Big Stocks Moving Higher On Friday

WIIM

ACADIA Pharmaceuticals shares are trading higher after a court decision ruled in favor of the company regarding patent infringement claims over Nuplazid.

<a href="https://storage.courtlistener.com/recap/gov.uscourts.ded.80479/gov.uscourts.ded.80479.141.0.pdf" title="https://storage.courtlistener.com/recap/gov.uscourts.ded.80479/gov.uscourts.ded.80479.141.0.pdf">https://storage.courtlistener.com/recap/gov.uscourts.ded.80479/gov.uscourts.ded.80479.141.0.pdf</a>

Legal

Court Determines ACADIA Pharmaceuticals Demonstrated Evidence That Aurobindo Infringes Claims 4 And 5 Of U.S. Patent No. 11,452,721

Offerings

ACADIA Pharmaceuticals Files For Offering Of Up To 43.6M Shares Of Common Stock By The Selling Stockholders

ACADIA Pharmaceuticals shares are trading higher after the company reported better-than-expected Q1 financial results.

ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) affirms FY2025 sales outlook from $1.03 billion-$1.09 billion to $1.03 billion-$1.09 billion vs $1.06 billion estimate.

Guidance

ACADIA Pharmaceuticals Affirms FY2025 Sales Guidance of $1.03B-$1.09B vs $1.06B Est

ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) reported quarterly earnings of $0.11 per share which beat the analyst consensus estimate of $0.06 by 83.33 percent. This is a 10 percent increase over earnings of $0.10 per share from the same period last year. The company reported quarterly sales of $244.32 million which beat the analyst consensus estimate of $239.34 million by 2.08 percent. This is a 18.70 percent increase over sales of $205.83 million the same period last year.

Comments

ACADIA Pharmaceuticals

Notizie

Ultime notizie per ACADIA Pharmaceuticals (NASDAQ:ACAD) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO